• Regulatory NewsRegulatory News

    FDA Approves Pfizer’s Mylotarg 7 Years After it was Pulled From the Market

    The US Food and Drug Administration (FDA) on Friday approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML) and for patients aged two years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment.  In 2010, Pfizer voluntarily withdrew the treatment, 10 years after it won accelerated approval, wh...